title: [Response to vaccination against the etiologic agent of viral hepatitis B (HBV) in a population at risk].
abstract: We report the results of the vaccinations against hepatitis B carried out with vaccine H-B-VAX of the commercial firm (Merck Sharp and Dohme), on 102 U.S.L. 32 hospital workers in Portomaggiore (Ferrara, Italy). The vaccine rendered 92% of the subjects inoculated immune and the incidence of secondary effects was low.
authors.affiliation: Laboratorio di analisi chimico-cliniche e microbiologiche, U.S.L. 32 Emilia Romagna, Portomaggiore, Ferrara.
authors.forename: M
authors.initials: M
authors.lastname: Lavezzi
authors.forename: A
authors.initials: A
authors.lastname: Donati
authors.forename: D
authors.initials: D
authors.lastname: Davi
authors.forename: M C
authors.initials: MC
authors.lastname: Carpanelli
authors.forename: S
authors.initials: S
authors.lastname: Farinelli
authors.forename: E
authors.initials: E
authors.lastname: Soracco
mesh_terms: D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D012307:Risk Factors; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines
vernacular_title: Risposta alla vaccinazione contro l'agente eziologico dell'epatite virale B (HBV) in una popolazione a rischio.